Vectus Biosystems Limited announced that the third of the five planned cohorts in the Single Ascending Dose (S.A.D.) segment of its first in human trial "A phase I/Ib, first-time-in-human, single centre, double-blind, randomized, placebo-controlled, dose escalating study of the safety, tolerability and pharmacokinetics of single and repeat doses of VB0004 administered orally to healthy volunteers; and to patients with mild to moderate hypertension with low cardiovascular risk" has been reviewed by the Trial Safety Review Committee. The Trial Safety Review Committee, having reviewed the 2mg, 10mg and 30mg doses of VB0004, has now given approval to proceed to the next dose level of 100mg. Importantly, no adverse events were observed at any of the three doses of VB0004 studied to-date. The interim pharmacokinetic (PK) analysis shows that the plasma concentrations of VB0004 increase to maximal concentration (Tmax) approximately eight hours after dosing. Further, VB0004 has a plasma half-life (the time taken for the plasma concentration to decrease by 50%) of 9.5 to 10 hours. These preliminary data suggest that VB0004 will be amenable to once daily dosing, a desirable feature in medications for chronic conditions such as hypertension, heart failure, kidney failure and pulmonary fibrosis. The trial is registered on the Clinical Trials Protocol Registration and Results Systems (ClinicalTrials.gov) and has been provided with the identifier NCT04925050.